You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Tuberculosis. In the initial treatment and in re-treatment of patients with tuberculosis, RIFADIN must be used in conjunction with at least one other antituberculosis drug. Leprosy. In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal disease. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (RIFADIN is not indicated for the treatment of meningococcal infections). Haemophilus influenzae. Prophylaxis of household contacts of patients with H. influenzae type B.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Tuberculosis. In the initial treatment and in re-treatment of patients with tuberculosis, RIFADIN must be used in conjunction with at least one other antituberculosis drug. Leprosy. In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal disease. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (RIFADIN is not indicated for the treatment of meningococcal infections). Haemophilus influenzae. Prophylaxis of household contacts of patients with H. influenzae type B.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Tuberculosis. In the initial treatment and in re-treatment of patients with tuberculosis, RIFADIN must be used in conjunction with at least one other antituberculosis drug. Leprosy. In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal disease. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (RIFADIN is not indicated for the treatment of meningococcal infections). Haemophilus influenzae. Prophylaxis of household contacts of patients with H. influenzae type B.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Tuberculosis. In the initial treatment and in re-treatment of patients with tuberculosis, RIFADIN must be used in conjunction with at least one other antituberculosis drug. Leprosy. In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal disease. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (RIFADIN is not indicated for the treatment of meningococcal infections). Haemophilus influenzae. Prophylaxis of household contacts of patients with H. influenzae type B.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
